Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Pagano, Gennaro; Taylor, Kirsten I.; Anzures‐Cabrera, Judith; Marchesi, Maddalena; Simuni, Tanya; Marek, Kenneth; Postuma, Ronald B.; Pavese, Nicola; Stocchi, Fabrizio; Azulay, Jean‐Philippe; Mollenhauer, Brit; Manzanares, Lydia López; Russell, David; Boyd, James T.; Nicholas, Anthony P.; Luquin, M.R.; Hauser, Robert A.; Gasser, Thomas; Poewe, Werner; Ricci, Benedicte; Boulay, Anne; Vogt, Annamarie; Boess, Frank; Dukart, Juergen; D’Urso, Giulia; Finch, Rebecca; Zanigni, Stefano; Monnet, Annabelle; Pross, Nathalie; Hahn, Andrea; Svoboda, Hanno; Britschgi, Markus; Lipsmeier, Florian; Volkova-Volkmar, Ekaterina; Lindemann, Michael; Dziadek, Sebastian; Holiga, Štefan; Rukina, Daria; Kustermann, Thomas; Kerchner, Geoffrey A.; Fontoura, Paulo; Umbricht, Daniel; Doody, Rachelle S.; Nikolcheva, Tania; Bonni, Azad

doi:10.1056/nejmoa2202867

articleNew England Journal of MedicineAug 3, 2022BRONZE OA

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

GPGennaro Pagano KIKirsten I. Taylor JAJudith Anzures‐Cabrera MMMaddalena Marchesi TSTanya Simuni

Roche (Switzerland)

PubMed

Indexed incrossrefpubmed

Abstract

Background

Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease.

Methods

I-ioflupane single-photon-emission computed tomography (SPECT).

Citation impact

385

total citations

FWCI: 43.44
Percentile: 100%
References: 16

Citations per year

Authors

45

Topics & keywords

Topics

Keywords

Parkinson's disease
Stage (stratigraphy)
Medicine
Disease
Internal medicine
Biology
Paleontology

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.